ABSTRACT
history and physical examination results, significantly facilitate diagnosis. New markers are also regularly announced, and these can serve as guides in the diagnosis of abdominal pain. [1] Biochemical markers, such as D-dimer and C-reactive protein (CRP), have been studied in the differential diagnosis of patients with acute abdominal pain, particularly those requiring surgical intervention, and these parameters have been
INTRODUCTION
Patients with abdominal pain represent a group frequently seen in the emergency department (ED). A differential diagnosis of a patient with acute abdominal pain is the duty and responsibility of the emergency physician. Various markers are useful. Laboratory test results, in addition to the patient's reported to be potential markers of the need for surgery in patients with undiagnosed acute abdominal pain. [2] Irisin is recognized as an exercise hormone originating from skeletal muscle. [3] In addition to skeletal muscle, it is also produced in other sites, such as fat, the liver, the heart, and salivary gland tissues. [4] [5] [6] Irisin is a version of the fibronectin type III domain-containing 5 (FNDC5) protein, which regulates the release of irisin from muscle cells. [7] The irisin precursor FNDC5 mRNA has been reported to be released from tissues such as the ovaries, the adrenal gland, the vena cava, the kidney, the urethra, the bladder, the liver, and the small intestines. [4] Bakal et al. [8] reported increased irisin levels in cases of acute appendicitis (AA). The purpose of the present study was to assess whether adding measurement of the blood irisin level to the routine blood work-up would be useful in establishing a diagnosis in patients presenting with acute abdominal pain.
MATERIALS AND METHODS

Study Design and Setting
This research was performed as a single-center, prospective, and cross-sectional study. Following receipt of ethics committee approval (Haseki Training and Research Hospital (2016/297), patients presenting at the ED with non-specific acute abdominal pain were reviewed for inclusion in the study. This hospital ED treats approximately 200,000 patients a year. Approximately 2% of these patients present with abdominal pain.
Participants
Patients aged 18 years or more and presenting at the ED with acute abdominal pain ongoing for fewer than 7 days were included in a 3-month study. The only eligibility criteria were age and presentation with acute abdominal pain at the ED. The participants were enrolled by the emergency physician on duty based on the chief complaint. Pregnant patients, and those determined to have liver failure, anorexia nervosa, acute myocardial infarction (AMI) or ischemic heart disease, metabolic syndrome, or diabetes mellitus, which might affect blood irisin levels, and those under 18 years of age were excluded. A total of 140 healthy volunteers were also recruited as a control group for the study.
Sex, age, weight, height, length of time of pain until presentation at the ED, and blood leukocyte, CRP, amylase, and creatine kinase (CK) values of patients were recorded on patient forms. The blood irisin level was expressed as microgram/ milliliter (mcg/mL) and the level observed in the patient and control groups was compared. The patients were diagnosed on the basis of anamnesis, physical examination, biochemical blood tests, and radiological imaging, as well as operation specimens collected from patients undergoing surgery following the requisite consultations.
Blood Irisin Measurements
Human irisin enzyme-linked immunosorbent assay kits (Catalog No. CK-E90905; Hangzhou Eastbiopharm Co., Ltd., Hangzhou, China) were used to determine irisin levels, according to the manufacturer's instructions. Specimen absorbance was determined using a Biotek ELX800 microplate reader (Biotek Instruments, Inc., Winooski, VT, USA) at a wavelength of 450 nm. The results were expressed in µg/mL. The minimum detectable level was 0.05 µg/mL.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows, Version 15.0 (SPSS Inc., Chicago, IL, USA) software. Descriptive data were expressed as numbers and percentages for categorical variables, and as mean, SD, minimum, maximum, and median for numerical variables. Student's t-test was used for comparisons between 2 groups of numerical variables when normal distribution conditions were established, and the Mann-Whitney U test was applied when normal distribution was not established. One-way analysis of variance and the Kruskal-Wallis test were used for comparisons between more than 2 groups. Subgroup analyses of comparisons of more than 2 groups were performed using the Mann-Whitney U test with a Bonferroni correction. Correlations between numerical variables were examined using Spearman correlation analysis since parametric test conditions were not established. P<0.05 was regarded as statistically significant.
The sample size was calculated to be of sufficient size to predict a small to medium-size effect in the difference of irisin levels in 2 independent groups with an alpha-error of 0.05 and 95% power.
RESULTS
A total of 213 patients and a 140-member healthy control group were included in the study. In all, 185 patients were excluded for following reasons: pregnancy (n=16), liver failure (n=7), anorexia nervosa (n=3), ischemic heart disease (n=35), metabolic syndrome or diabetes mellitus (n=37), and those who declined to participate in the study (n=85). . The difference between the mean BMI value of the patient and control groups was not statistically significant (p=0.074).
The mean irisin value in the patient group was 6.8±3.2 mcg/ mL (range: 0.2-13.6 mcg/mL), compared with 5.7±2.1 mcg/ mL (range: 0.2-10.5 mcg/mL) in the control group. The difference between the mean irisin level in the patient group and the control group was statistically significant (p=0.005). However, no statistically significant difference was determined in the mean irisin level when analyzed according to gender (p=0.108) ( Table 2 , Fig. 1) .
When the irisin level in the patient group was compared with that of the control group, the irisin level in the patient group was determined to be significantly higher in those with AA (Mean±SD: 8.59±3.61 mcg/mL, range: 6.67-10.51 mcg/ mL), urolithiasis (Mean±SD: 7.55±3.07, range: 6.38-8.72) and gallbladder subgroups (Mean±SD: 7.57±2.49, range: 6.51-8.62) compared with the control group (p=0.007, p=0.007, p=0.001). Diagnoses in the ED demonstrating prevalence and irisin level are provided in Table 3 and Figure 2. 
DISCUSSION
The blood irisin level of patients presenting with acute abdominal pain was significantly higher compared with that of the healthy control group in this study. Analysis of the diagnostic subgroups revealed that the blood irisin level was higher in the patients with AA, biliary colic, and colic in the urinary tract than in the control group. Higher blood levels in patients with diseases involving narrowing or obstruction of the tubular appendix vermiformis or the urinary or biliary tract suggested that irisin may be a potential marker in the diagnosis of these diseases. Bakal et al. [8] investigated the irisin level in blood, urine, and saliva in pediatric patients with AA. They also used immunohistochemical methods to determine the blood irisin level in diseased appendix vermiformis tissue. Patients with AA had a higher irisin level compared with the control group. When they followed up with these patients after surgery, they observed a dramatic drop in the irisin level. They suggested that irisin together with an increase in neutrophil level might be a good marker in cases of AA. The results reported by Bakal et al. support our own research. The blood irisin level in patients diagnosed with AA in our study was higher than that of the control group.
Irisin level has thus far only been investigated in AA among patients with acute abdominal pain, and ours is the first study to investigate irisin level in all types of non-traumatic acute abdominal pain. The present study is valuable in terms of determining that there were high blood irisin levels in biliary colic and urolithiasis as well as AA. The determination of a high blood irisin level in the pathology of organs with a tubular structure can assist with the exclusion of other etiological causes of abdominal pain.
Blood irisin level has already been investigated in several diseases. Numerous studies have linked it to muscle mass and insulin resistance, leading to investigation of potential cardiovascular effects. The potential influence in chronic kidney failure, some cancers, metabolic disease, non-alcoholic liver disease, and osteoporosis have also been examined; however, irisin has been assessed more as a hormone than as a biochemical marker. [9] The present study indicates that irisin may be a biochemical marker in some specific groups of conditions featuring abdominal pain.
Aydın et al. [10] investigated the irisin level in serum and saliva in patients who experienced AMI. The serum and saliva levels of irisin measured at the time of presentation and after 72 hours were elevated, while the CK and CK-MB levels were decreased. They suggested that a low irisin level in the early period might be used as a biomarker to support a diagnosis of AMI. An interesting aspect of that study is that, using immunohistochemistry, they were able to demonstrate that not only the striated muscle of the salivary glands, but also the lumen, was able to secrete irisin. Their study is evidence that some proteins can be produced in the salivary glands and acinar cells.
The common feature of the structures of gastrointestinal, biliary, and urinary tract organs is that they are tubular organs with a smooth muscle structure. [11] The pathophysiology of this diagnostic group of diseases associated with a high irisin level included early luminal narrowing and obstruction in the late phase. Distension occurring due to increasing hydrostatic pressure in the proximal part following obstruction stimulates tubular organ peristalsis. [12] [13] [14] [15] This smooth muscle mass with increasing peristalsis can be postulated to give rise to increased irisin production either itself, or through interaction with other autocrine and endocrine organs under the influence of inflammation caused by the obstruction.
Irisin was once thought to be released only by skeletal muscle, but has since been shown to be secreted by other organs as well. [3, 6, 16, 17] Irisin release in tubular organ diseases may be confirmed with additional immunohistochemical studies. In the present study it was observed that the irisin level in cases of peptic ulcer, a disease of the stomach, which is a tubular organ and part of the gastrointestinal tract with a smooth muscle wall, did not increase compared with the level of the control group. This may have been a result of narrowing or obstruction of the lumen not related to the physiopathology of peptic ulcer. [11, 18] No single biomarker would be sufficient to distinguish the inflammatory condition of tubular organs (e.g., AA, renal colic) per se. Nonetheless, the present findings suggest that irisin may be useful in the differential diagnosis. Acar et al. [19] examined many variables, including serum leukocytes, lymphocytes, neutrophils, neutrophil-lymphocyte ratio, and mean platelet volume, in the diagnosis of tubular organ inflammation. They suggested that these biomarkers could be useful parameters to discriminate and diagnose these conditions, since the level was often higher in those with AA or renal colic than that seen in healthy controls. Similarly, the results of the present research also suggest that the irisin value may be useful in the specific diagnosis of patients with acute abdominal conditions.
Limitations
The major limitation of this study is the small number of patients included in the sample. In addition, the group assessed was limited only to adults with acute abdominal pain who presented at the ED and was not further refined. Another weakness of this study is that irisin levels were not evaluated immunohistochemically. A further limitation is that the blood irisin level was not monitored after our patients were admitted to the ED. We think that future studies on the causes of acute abdominal pain occurring due to tubular organ obstruction will test our findings.
Conclusion
In conclusion, the blood irisin level may be useful in the differential diagnosis of diseases involving narrowing or obstruction of tubular organs in patients presenting at the ED with acute abdominal pain.
